Category Archives: Science Research Technology

Science Research Technology

Transnational network for personalised medicine

Launch of Interreg project „Codex4SMEs“ on the development of companion diagnostics

Transnational network for personalised medicine

Dr Margot Jehle is project leader of the Interreg project Codex4SMEs. (Source: BioRegio STERN Management GmbH/Andreas Körner)

(Stuttgart) – BioRegio STERN Management GmbH is the German lead partner for the Interreg project Codex4SMEs. The aim of this project is to build a transnational network to accelerate the development of companion diagnostics throughout the whole value chain for small and medium-sized businesses. The project has been endowed with a total budget of 3.13 million euros as part of the Interreg North-West Europe (INTERREG NWE) programme. „Interreg“ forms part of the structural and investment policy of the European Union, supporting cross-border cooperation between regions and cities.

Companion diagnostics are essential to the field of „personalised medicine“. They allow tests to determine the molecular causes of a disease before treatment is started. This allows every patient to receive personalised medication in the correct dosage and at the right time. However, thus far the development of companion diagnostics has been highly time-consuming and costly, so at present it is only used in the context of very few treatments. The Codex4SMEs project (Companion Diagnostics expedited for small and medium-sized enterprises) will involve the establishment of a network of nine partners and two sub-partners from seven countries, to assist companies with the development of such services:

– from Ireland, the bodies involved are WestBIC (EU Business and Innovation Centre for Irelands Border, Midlands and Western Region) and CURAM (the Science Foundation Ireland Centre for Research in Medical Devices at NUI Galway),
– from England, the University of Leicester, with Medilink Midlands as a regional sub-partner,
– from France, the Medicen Paris Region cluster,
– from the Netherlands, BOM Holding BV (technology funding body Brabantse Ontwikkelings Maatschappij) and the Innovation Quarter, with a regional sub-partner,
– from Luxembourg, the Integrated BioBank of Luxembourg – IBBL, and
– from Austria, the Biobank Graz at the Medical University of Graz.

„The combination of regional economic development organisations and biobanks creates the ideal conditions to provide companies with direct access to specific expertise such as the verification of biomarkers, in other words parameters of biological processes as indicators of diseases“, says project leader Dr Margot Jehle of BioRegio STERN Management GmbH.

The project has a total budget of 3.13 million euros as part of the Interreg North-West Europe (INTERREG NWE) programme. BioRegio STERN Management GmbH is the lead partner; for the project term of three years it will receive close to 640,000 euros, of which 60 per cent will come from subsidies. The kick-off meeting with all of the partners will take place on 29 and 30 January 2018 in Stuttgart.

About BioRegio STERN Management GmbH:
BioRegio STERN Management GmbH is a skill-sharing network, providing a help and ad-vice centre for founders of new businesses, entrepreneurs and researchers in the life sciences sector in the cities of Stuttgart, Tübingen, Esslingen and Reutlingen and the Stuttgart and Neckar-Alb regions. BioRegio STERN Management GmbH represents the interests of these market players in dealings with political circles, the media and associations and provides advice on grant applications and corporate financing. Key focal points include regenerative medicine, medical technology and the automation of biotechnology. Managing Director Dr. Klaus Eichenberg is a molecular and cell biologist and investment analyst.

Company-Contact
BioRegio STERN Management GmbH
Klaus Eichenberg
Friedrichstrasse 10
70174 Stuttgart
Phone: +49 (0)711-870354-0
E-Mail: info@bioregio-stern.de
Url: http://www.bioregio-stern.de/en

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Strasse 58a
70184 Stuttgart
Phone: +49 (0)711-6070719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Specialists discuss visual prostheses for blind people

Retina Implant AG at „Artificial Vision 2017“ research congress in Aachen

Specialists discuss visual prostheses for blind people

Dr. Alfred Stett, CTO Retina Implant AG (Source: Retina Implant AG)

(Reutlingen/Aachen) – Retina Implant AG presented the latest research results on its subretinal implant at the „Artificial Vision“ conference in Aachen in early December. This international symposium on visual prostheses is organised by RWTH Aachen University. It is regarded as an unmissable European event for specialists in the field of „artificial vision“.

Research into artificial vision using prostheses has been under way since the 1960s. Following initial promising findings in the 1990s, major technological advances have led to further tangible results in the last few years. As early as 2008, a previously completely blind patient was able to make out his name, written in 8 cm white letters on a black background, using the subretinal implant from Reutlingen-based Retina Implant AG. Since then, the expectations placed on the electronic implants have increased continuously. Most patients with an implanted chip can identify light sources, which makes it easier for them, for example, to find their way around a room again.

„Now our job is to meet the high expectations raised by our initial successes,“ explained Dr. Alfred Stett, CTO of Retina Implant AG. „We“ve been able to sufficiently prove that our implant can restore partial sight to people who perceive very little or no light as a result of retinitis pigmentosa. At „Artificial Vision“, we had extensive discussions about the technical and medical challenges that still need to be overcome.“ These include the service life of implants, which need to function in the body without a hermetic casing over many years, vision-training and rehabilitation after the implant has been activated as well as re-implantations. „Once again, the symposium showed there is now a very wide range of different technical and surgical methods for implants. However, the experts all agreed that visual prostheses offer real prospects for patients who became blind as a result of a degenerative retinal disease.“

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Volker Hiller
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 282
E-Mail: volker.hiller@retina-implant.de
Url: https://www.retina-implant.de/en/

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Prize draw to win an ARTS 2018 „expertise4innovations“ calendar

Prize draw to win an ARTS 2018 "expertise4innovations" calendar

ARTS photo calendar was created in cooperation with Wolfram Schroll & Airbus.

With its 2018 expertise4innovations campaign, ARTS will be using its new calendar to showcase a different innovation in the fields of space and aviation each month. The campaign also includes a series of specialist blog articles of the same name, each of which will appear on the first of the month, in which ARTS will not only feature the innovation as photographed, but will also describe its own efforts to promote innovation.

As the year draws to a close, ARTS will be holding a prize draw, enabling five entrants to win a calendar featuring the work of the photographer, Wolfram Scholl, who has been a specialist industrial photographer for over twelve years, working for small businesses and large companies including Airbus, Siemens and Bosch. His main focus is on light industrial engineering, the steel industry, medical technology, research, and aerospace sectors, with photo sessions sometimes lasting for several weeks and taking him all over the world. For the Airbus photo series, he visited nine research and development laboratories in Germany, France, Spain and Great Britain, meeting the challenge of capturing innovative technologies such as space radar echo chambers, the inner technical workings of satellites, acoustic laboratories, and many more.

Anyone who is interested in taking part in the draw can send an e-mail with the subject „ARTS Prize Draw“, their name and e-mail address to marketing@arts.aero by 31 December 2017. The draw will take place within a week of the closing date and ARTS will notify the winners by e-mail. The privacy policy and entry conditions of ARTS Holding SE apply.
http://expertise4innovations.com/
https://arts.aero/downloads/conditions-of-participation
https://arts.aero/data-privacy-statement

ARTS (Aircraft Related Technical Service) supports the aerospace industry world-wide with expertise: With people and their knowledge or turnkey solutions. With six branches and over 25 project sites, more than 500 technical and commercial experts are active in ARTS. With its expertise in the aerospace industry, ARTS provides customers with new ideas and additional capacity, enabling them to overcome bottlenecks and concentrate on their core business. Three fields of service are united under the umbrella brand ARTS: Experts, Processes and Solutions. Each service field is the responsibility of an independent ARTS company within the ARTS group.

Contact
ARTS Holding SE
Melanie Wolf
Hermann-Reichelt-Str 3
01109 Dresden
Phone: +49351795808-42
Fax: +49351795808-17
E-Mail: melanie.wolf@arts.aero
Url: http://www.arts.aero

Science Research Technology

Two-arm robot optimises production of nanoparticles

Joint BMBF APRONA project launched – development of an automation solution to produce nanoparticles for life sciences

Two-arm robot optimises production of nanoparticles

The partners of the joint BMBF APRONA project at kick-off in Tübingen (Source: BioRegio STERN/Anne Faden)

(Stuttgart) – BioRegio STERN Management GmbH is the coordinator of the new joint APRONA project launched in September 2017. A „flexible robot-based platform for automated production of nanoparticles“ is to be developed within the next two and a half years. The project is receiving funding of around EUR 1.6 million as part of the initiative by the German Federal Ministry of Education and Research (BMBF) to promote SME-focused, strategic R&D partnerships in networks and clusters (KMU-NetC).

The Greek word „nános“ means „dwarf“, and yet the expectations placed on nanoparticles are enormous. These tiny particles are now found not only in a multitude of everyday products – for example, to extend shelf life – but are also used in countless applications in medicine, medical technology and the pharmaceutical industry. Nanotechnology is designed to help diagnose diseases earlier, deliver active ingredients faster to the target location in the body and improve implant tolerance. However, hardly any automation solutions are currently available that are suitable for the complex manufacturing processes. For instance, if nanoparticles are to be used in personalised medicine, reproducible product characteristics need to be ensured and regulatory requirements met. A „flexible robot-based platform for automated production of nanoparticles“ – APRONA – is to be developed to close the gaps. The joint project is part of the BMBF initiative to promote SME-focused, strategic R&D partnerships in networks and clusters (KMU-NetC) and was launched in September 2017 with BioRegio STERN Management GmbH as the coordinator.

For ten years, BioRegio STERN Management GmbH has been working successfully on strategies to initiate industry links between the medtech and biotech sectors. APRONA is now the next step in cluster development, following on from the ELSA – Engineering Life Sciences Automation – project, which drove forward collaboration between the life sciences and engineer-driven industries. Three small and medium-sized businesses from the STERN BioRegion offer automation and life science expertise in the joint project.

Goldfuss engineering GmbH, based in Balingen, specialises in special-purpose mechanical and systems engineering, with its „Lab automation“ division designing complex solutions for fully automatic processes for sectors such as the life sciences.
Tübingen-based Biametrics GmbH develops and produces analytical devices for molecular interaction analysis. Its SCORE (single color reflectometry) detection method can be used to detect any molecular interaction, for example in chemosensor technology to identify nanoparticles in consumer goods.
BioTeSys GmbH, from Esslingen, specialises in analysing and evaluating the impact of bioactive substances – in other words, examining a substance’s functional properties and its effects and effectiveness. The Fraunhofer Translation Centre for Regenerative Therapies in Würzburg forms a link between these project partners from the engineering and material science and biotech industries. The centre is part of the Fraunhofer Institute for Silicate Research ISC and brings together expertise from a wide range of scientific disciplines such as materials research and regenerative medicine for application in a clinical setting.

As part of the APRONA project, these four project partners will be initiating automated production of nanoparticles for application in diagnostics and treatment. The particles can be used for drug delivery systems and for the transfer of active ingredients to the part of the body where they are needed. The aim of the joint research and development project, which will run for two and a half years, is to create a versatile, interactive robot technology to produce nanoparticles. The plan is to implement the automation process using a two-arm robot that interacts with other devices. To achieve this, all the equipment and components in the system need to be developed and combined in such a way that all the necessary motion sequences, speeds, positioning movements, and signal and measurement parameters ensure the production workflow is sufficiently precise and reproducible. All devices must therefore be compatible with each other and capable of being combined.

„Ultimately, everyone involved will benefit from the innovation network and together achieve the goal of a reliable and automated production method for nanoparticles in life sciences,“ says project coordinator Dr. Verena Grimm from BioRegio STERN Management GmbH.

About BioRegio STERN Management GmbH:
BioRegio STERN Management GmbH is a skill-sharing network, providing a help and ad-vice centre for founders of new businesses, entrepreneurs and researchers in the life sciences sector in the cities of Stuttgart, Tübingen, Esslingen and Reutlingen and the Stuttgart and Neckar-Alb regions. BioRegio STERN Management GmbH represents the interests of these market players in dealings with political circles, the media and associations and provides advice on grant applications and corporate financing. Key focal points include regenerative medicine, medical technology and the automation of biotechnology. Managing Director Dr. Klaus Eichenberg is a molecular and cell biologist and investment analyst.

Company-Contact
BioRegio STERN Management GmbH
Klaus Eichenberg
Friedrichstrasse 10
70174 Stuttgart
Phone: +49 (0)711-870354-0
E-Mail: info@bioregio-stern.de
Url: http://www.bioregio-stern.de/en

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70174 Stuttgart
Phone: +49 (0)711-6070719
E-Mail: info@zeeb.info
Url: http://www.zeeb.info

Science Research Technology

Demo Day – startups that transcend borders

Teams in 100-day MedTech Startup School 2017 present their ideas

Demo Day - startups that transcend borders

The teams from MedTech Startup School at Demo Day 2017 (Source: BioRegio STERN/Michael Latz)

(Stuttgart/Tübingen) – The third MedTech Demo Day, organised by the MedTech Startup School and BioRegio STERN Management GmbH, was held at the Bootshaus am Neckar in Tübingen in October. The organisers joined forces with Medical Innovations Incubator GmbH, the Medical Innovations Foundation, the University Hospital of Tübingen and the University of Tübingen’s Technology Transfer Office to stage the Demo Day. This marked the end of a 100-day innovation training programme for ten teams of researchers, doctors and students. All the teams were able to present their ideas for founding new medtech businesses to potential investors, business experts and healthcare specialists.

In July 2017, the ten teams embarked on their 100-day innovation training programme at the MedTech Startup School. Lawyers, business experts, scientists and doctors explained to the young researchers from a wide range of sectors what makes a good business model and how a startup company works. The teams presented the ideas they had developed to an audience of eminent figures from business and research. The judges were then each able to vote for their favourite.

This year’s winner was „Prometheus Science“, whose team presented an open source platform for developing technical equipment. Data, designs and design studies are placed on the platform to eliminate the costly and time-consuming development process for lab technicians by using collective intelligence. The first product that has been developed in this way is the „FlyPi“ all-in-one biotech lab for detecting and investigating parasites in blood.
Second place went to the „Elastigenics“ team, which combines elastin-specific antibodies and nanoparticles charged with a special active ingredient. The aim of these therapeutic active ingredients is to restore vital elastin, which is responsible for the elongation of blood vessels and is reduced with age.
The third prize was won by „PlasPatch“ for the development of a mobile device to produce an innovative plasma plaster. Using cold atmospheric plasma technology, PlasPatch can produce the material to treat chronic wounds in patients at home.

All the teams demonstrated an exceptional interdisciplinary approach. The impressive innovations would not have been possible without the collaboration between biologists, medical specialists, IT experts and engineers. This was also lauded by Dr. Christoph Zrenner, co-initiator of the MedTech Startup School, from the University Hospital of Tübingen: „Now in its third year, the Startup School has already become an established tool for creating innovations. I’m particularly pleased we can already reap the rewards of the last few years.“ A number of projects presented in the first two years have already secured funding and investment. Dr. Verena Grimm, project manager at BioRegio STERN Management GmbH, was impressed with the competition’s international dimension: „The MedTech Startup School is now one of the leading events of this kind in Germany. The international make-up of the teams shows it has long made a name for itself beyond national borders.“

The project is funded by Baden-Württemberg’s State Ministry of Economic Affairs, Labour and Housing, the German Federal Ministry of Education and Research and IFEX, an initiative for founding new businesses and company succession.

About BioRegio STERN Management GmbH:
BioRegio STERN Management GmbH is a skill-sharing network, providing a help and ad-vice centre for founders of new businesses, entrepreneurs and researchers in the life sciences sector in the cities of Stuttgart, Tübingen, Esslingen and Reutlingen and the Stuttgart and Neckar-Alb regions. BioRegio STERN Management GmbH represents the interests of these market players in dealings with political circles, the media and associations and provides advice on grant applications and corporate financing. Key focal points include regenerative medicine, medical technology and the automation of biotechnology. Managing Director Dr. Klaus Eichenberg is a molecular and cell biologist and investment analyst.

Company-Contact
BioRegio STERN Management GmbH
Klaus Eichenberg
Friedrichstrasse 10
70174 Stuttgart
Phone: +49 (0)711-870354-0
E-Mail: info@bioregio-stern.de
Url: http://www.bioregio-stern.de/en

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70174 Stuttgart
Phone: +49 (0)711-6070719
E-Mail: info@zeeb.info
Url: http://www.zeeb.info

Science Research Technology

Innovative 3D Software in Additive Manufacturing

Innovative 3D Software in Additive Manufacturing

(Source: CoreTechnologie GmbH)

The German-French software producer CoreTechnologie is presenting its new 3D additive manufacturing software at this year’s trade fair Formnext. With the innovative tool, CAD data of all common formats for 3D printing processes can be processed and analyzed with special test profiles with regard to the different rapid manufacturing procedures.

Data Processing with B-Rep Solids

Especially for metal printing processes, the new 3D additive manufacturing software can be used to create support structures for production as well as latice geometries for lightweight construction and material savings. The CAD models can be used as intelligent B-Rep geometry by robust direct modeling functions, which has significant advantages over the machining of tessellated models. The clear graphic interface of the system allows a direct and easy modification of critical geometry areas as well as the reduction of the complexity of the parts to be printed.

Optimal Utilization of the Installation Space

By freely selectable slicing parameters, the roughness is displayed and the components can be automatically positioned by the system in such a way that selected areas have the best possible surface. The database contains standard machine types with their building spaces. Intelligent nesting functions ensure fast simple filling for optimal utilization of the building space and thus maximum efficiency.

Flexibility and Data Quality

The 3D additive manufacturing software has sophisticated interfaces for CATIA, NX, SolidWorks, Creo, JT, STEP and many more. The healing functions of the system ensure the best possible data quality of the converted models optimized for 3D printing, which can be stored in the amf, 3mf and stl formats. This ensures that quality mesh models are sent to the printer.

The innovative 3D software will be presented to interested parties at the trade fair Formnext from November 14th to 17th, 2017 in Frankfurt in Hall 3.0 at booth C68.

For further information, please visit www.coretechnologie.com
+++

Since its foundation in 1998, the software manufacturer CoreTechnologie with locations in Germany, France, USA, Japan and Great Britain has been led by the managing directors Dominique Arnault and Armin Brüning. With innovative products, the visionary company has consistently optimised its product portfolio and secured the technological leadership in the area of conversion software. Each year, CoreTechnologie invests more than 30 per cent of sales in the research and implementation of new technologies and has the most complete product range in this field.

In the focus of technology development is the product line of „3D Evolution“ which guarantees efficient and lossless exchange of complex data structures between independent and heterogeneous CAX software solutions. With extremely powerful native interfaces for all leading CAD systems and for conversion of all common 3D formats, the software module ensures optimal interoperability of most various IT solutions.

Apart from providing visualisation and manufacturing data across most various systems, CoreTechnologie offers outstanding technologies for automatic data correction, feature-based conversion, geometry optimisation, quality control and long-time archiving as well as for visualisation of complex 3D models. The software components for software manufacturers of the most different CAX applications are the company“s second leg.

The customer portfolio of CoreTechnologie comprises more than 400 companies from the automotive, aerospace, engineering and consumer goods industry who are in many cases the quality leaders in their relevant segment.

Company-Contact
Core Technologie GmbH
Armin Brüning
Klinger 5
63776 Mömbris
Phone: 0049 6029 98 999 10
E-Mail: info@de.coretechnologie.com
Url: http://www.coretechnologie.com

Press
PR Solutions by Melanie Schacker
Melanie Schacker
Am Nonnenhof 55
60435 Frankfurt/Main
Phone: 0049 69 95 20 8991
Fax: 0049 69 95 20 8992
E-Mail: presse@pr-schacker.de
Url: http://www.pr-schacker.de

Science Research Technology

Digital length gauges by WayCon – extremely accurate and versatile

Digital length gauges by WayCon - extremely accurate and versatile

Digital Length Gauges ST and MT

WayCon Positionsmesstechnik has added digital length gauges from the HEIDENHAIN SPECTO (ST) and METRO (MT) series to its product range. The length gauges feature an outstanding accuracy of up to +/-0.2 μm over measuring ranges up to 30 mm. Waycon length gauges have many versatile applications, as the plungers can be actuated pneumatically or by the measured object. They are suitable for use in production metrology, multipoint inspection stations, measuring equipment monitoring, or as position encoders.

The digital length gauges are quick, reliable, and accurate. Their robust design and high thermal stability allows them to also be used in production equipment and machines. The SPECTO range has an IP rating of up to IP67.

Their compact structure allows for several gauges to be combined effectively to simultaneously measure different points of an object. The incremental output signal produced by the gauge can be directly connected to a PLC or the measured values can be displayed on a digital readout (DRO) on site.

For more information please visit: www.waycon.biz/products/digital-gauges/

WayConPositionsmesstechnik GmbH has been developing and manufacturing precision sensors for position and distance measurement since 1999. As an innovative company with headquarters in Taufkirchen near Munich and a branch in Brühl near Cologne, we sell our products all over the world. Our goal is to provide our customers with the best possible measurement technique solution: from high-quality sensors from the standard range to customer-specific solutions, from prototype to series production – for the most varied applications in industry and research. The products made in Taufkirchen are subject to rigorous quality standards and every single one is delivered to our customers with a calibration certificate.

Company-Contact
Waycon Positionsmesstechnik GmbH
Marcus Venghaus
Mehlbeerenstr 4
82024 Taufkirchen
Phone: 089-67-9713-0
E-Mail: info@waycon.de
Url: http://www.waycon.biz

Press
Waycon Positionsmesstechnik GmbH
Marcus Venghaus
Mehlbeerenstr. 4
82024 Taufkirchen
Phone: +49 89 679713-0
E-Mail: presse@waycon.de
Url: http://www.waycon.biz

Science Research Technology

ERN-EYE: a European reference network dedicated to rare eye diseases

7th SIOG congress of the Italian Society for Genetic Ophthalmology

ERN-EYE: a European reference network dedicated to rare eye diseases

(Source: Retina Implant AG)

(Reutlingen/Naples) – The congress of the Italian Society for Genetic Ophthalmology (SIOG) was a prime example of successful collaboration. For this year’s event, medical professionals and scientists met in Naples to discuss research and treatments for rare eye diseases at a European level. Topics included collaboration within the ERDC (European Retinal Disease Consortium) and ERN-EYE, a European reference network dedicated to rare eye diseases. Prof. Eberhart Zrenner, who has been an internationally renowned specialist in the research and treatment of rare eye diseases for many years now, gave a presentation on neuro-stimulation and the effects of transepithelial electro-stimulation on the sight of patients with retinitis pigmentosa.

At this year’s congress of the Italian Society for Genetic Ophthalmology („Congresso SIOG – Società Italiana di Oftalmologia Genetica“) in Naples, Italy, specialists in rare eye diseases met to discuss research results and treatments, as well as new and existing opportunities for cooperation at a European level. To improve cross-border treatment and care for patients with rare eye diseases, the European Union and the member states launched 23 European Reference Networks (ERNs) at the start of 2017. Retina Implant AG welcomes and supports the development of the European Reference Network for Rare Eye Diseases (ERN-EYE).

The members of the network all have extensive experience in researching and treating rare eye diseases. The aim is to promote knowledge transfer between ERN experts and doctors, who will be able to query a database to find out for their patients which special treatment options are available for the relevant condition and where. „To support this Europe-wide patient referral system, treatment reimbursement should be regulated and harmonised on a transnational basis,“ explains Reinhard Rubow, CEO of Retina Implant AG. „For instance, a patient from Ireland could have our subretinal optic chip implanted at our implantation centre in Tübingen, and the costs would be reimbursed. ERN provides a framework that will allow future patients to be treated at the location in Europe that is most suitable for them.“

Working with patient associations such as Retina International is considered to be essential here, and the organisation’s president, Christina Fasser, raised the issue of patient perspective in Naples: „We must not leave anyone behind – everyone has a right to the best standards in diagnosis and treatment.“

„These closing words from Christina Fasser precisely reflect our own motivation to continue our research and development work,“ agrees Rubow. „Just recently, the French health authority HAS (Haute Autorite de Sante) approved our Forfait Innovation application to assess the benefits of our RETINA IMPLANT Alpha AMS subretinal implant,“ he adds. The accompanying Retina Implant AG study investigates the impact of the implant on the participants‘ daily lives. For the first time, patient-reported outcome surveys are being used that are specifically adjusted to low-vision patients and their social routines, age, language and life situations. The subretinal implant from Retina Implant AG can help restore partial sight to visually impaired patients who perceive very little or no light as a result of different forms of the degenerative retinal disease retinitis pigmentosa (RP).

In a lecture entitled „Close to the physiology of vision“, Prof. Eberhart Zrenner reported on patients who have had the chip implanted and have thus partially regained the function of degenerated photoreceptors. For instance, they can perceive light sources, which improves spatial orientation. „Clearly, Retina Implant AG not only develops innovative treatments and high-tech products for people who suffer from RP – we also engage with networks and the international scientific community to drive forward research in this area as a whole,“ Rubow sums up.

Retina Implant AG was a major supporter of the event.

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Ines Wülker
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 289
E-Mail: ines.wuelker@retina-implant.de
Url: https://www.retina-implant.de/en/

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Definiens broadens Immuno-Oncology service Offer

Washington, D.C., November 08, 2017 – With the start of the
32nd Annual Meeting (November 8th-12th) of the Society for
Immunotherapy of Cancer (SITC) in National Harbor, MD,
Definiens, the leader in Tissue Phenomics® and provider of endto-
end solutions for biomarker programs in immuno-oncology,
unveils its game changing Immuno-Oncology Panel (IO-Panel)
as parts of its groundbreaking new „Insights“-Services
portfolio.
The IO-Panel is a first in class powerful tool in Definiens new portfolio of
modular services. The IO-Panel empowers pharmaceutical immunooncology
(IO) researchers to advance tissue-biomarker-dependent drug
development and to speed up transfer to clinical research. Future
advancements in immuno-oncology depend on broader use of
standardized biomarkers for multiple treatment programs.
„The IO-Panel helps to harmonize and standardize the understanding on
the entire cancer Immune-landscape through an extendable set of seven
core biomarkers in combination with Definiens“ first in class Tissue-
Phonemics®-driven Image analysis services. It helps to remove
uncertainties and to accelerate that patients and healthcare systems
benefit faster from new precision therapies in immuno-oncology.“
comments Ralf Huss, Chief Medical Officer of Definiens.
Thomas Heydler, Chief Executive Officer of Definiens explains further:
„Definiens“ tailored end-to-end solution allows drug researchers to
develop predictive multi-biomarkers based on a defined standard to derisk
trial investments as well as efforts. It will help to accelerate immunooncology
drug development and more effective clinical trials“.
The IO-Panel combines Definiens“ leading digital image analysis
capabilities, powered by Tissue-Phenomics® technology and high-end
consulting services, delivered by a leading team of expert consultants.
Tissue-Phenomics® technology can quantify the relevant spatial relations
of different immuno and tumor cells within the context of the complete
tissue architecture and tumor heterogeneity. By correlating this
information with e.g. patient data, Definiens“ experts generate biological
insights that are needed for true precision medicine.
The IO-Panel is available through Definiens“ new and unique web-based
service platform known as „Insights“. It allows clients to easily access
Definiens“ entire Services portfolio and acts as a central data repository
which supports the collaboration with internal and external stakeholders
in a regulatory compliant environment.
„Definiens“ new modular service portfolio is a milestone for biomarkerdependent
drug development. Harmonizing biomarkers in pre-clinical and
clinical trial programs and adding multi-omics and treatment-data assures
data consistency and learnings across drug projects and indications. „
adds Heinz Oehl, VP Global Marketing and Corporate Business
Development at Definiens.
Definiens once again proves to be a main engine of innovation in immunooncology
and a key partner with expertise to support tissue-based
oncology biomarker programs from start to finish.
Please attend at The Society for Immunotherapy of Cancer’s (SITC) 2017
Pre-Conference „Immuno-Oncology Biomarkers: Today“s Imperatives for
Tomorrow“s Needs“ in National Harbor, MD, our presentation „Multiplex
IHC Immuno-Oncology Panel for Standardized Profiling of the Immune
Status Based on Spatial and Functional Characterization of the Tumor
Microenvironment“ on November 8, 2017 to learn more about the
comprehensive assessment of the immune status provided by Definiens“
IO Panel image and data analysis based on multiplex IHC assays provided
by Mosaic Laboratories, LLC., or visit us at the Definiens congress booth.

About Definiens
Improving patient lives by unlocking the tissue phenome
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune
system for that purpose. Our mission is to accelerate breakthroughs in immuno-oncology by helping
pharmaceutical researchers better leverage tissue-based information through Definiens Tissue Phenomics® –
technology. Our expertise accelerates and deepens understanding of disease biology and immune system
mechanisms and allows to bring multi-omics data into a cancer-relevant context, which facilitates the
translation of new insights into novel therapies and treatment strategies. Our vision is to create unique and
actionable patient profiles through harmonized biomarkers for an individualized standard of care, where
patients experience fewer side effects and live longer. Definiens“ proven technology has been used in
thousands of projects, yielding results that have accelerated drug development and produced over 650 peerreviewed
publications.
Definiens is a member of the AstraZeneca group providing products and services to companies across the life
sciences sector, including MedImmune, the global biologics research and development arm of AstraZeneca.
Definiens‘ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award
for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com
Safe Harbor Statement
This press release contains „forward-looking statements“ within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements relating to data being presented at the at the 2017 Society for
Immunotherapy of Cancer (SITC) held November 10-11, 2017 in National Harbor, MD. These „forward-looking
statements“ are based on management’s current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ materially and adversely from those described
or implied in the forward-looking statements.

Contact
Definiens AG
Heinz Oehl
Bernhard-Wicki-Straße 5
80636 München
Phone: +49 (0) 89 231180-00
E-Mail: press@definiens.com
Url: http://www.definiens.com

Science Research Technology

SKIDATA Innovathon: exploring digital trends

Employees and students develop new solutions for IT & SKIDATA technology

SKIDATA Innovathon: exploring digital trends

SKIDATA Innovathon: exploring digital trends

It´s that time again – namely, for the next round of the SKIDATA Innovathon. Experienced specialists, creative outside-the-box thinkers and inspiring newcomers will develop practical applications for SKIDATA´s digital future as part of the third SKIDATA Innovathon taking place from November 8-10, 2017. Anything goes at this event – anything except conventional ideas, that is. From big data to virtual reality or artificial intelligence: removed from everyday work, more than ten international teams from all divisions will work on fresh, new concepts. Because together we create the best ideas.

„At SKIDATA, we have employees with many creative ideas and a strong pioneering spirit. With the Innovathon, we want to give them the chance to develop and utilize this power of innovation in an inspiring think tank atmosphere and in interdisciplinary teams“, explains Wolfgang Titze, Head of Software Development in Salzburg and co-organizer of the SKIDATA Innovathon. In addition to being a think tank for the company, however, this event has a social component which is also very valuable. Working together on an idea for days unites us.

Innovation is a result of professional teamwork

This is the third time the Innovathon has taken place and it has already established itself as an internal forum for innovation. Each year the number of participants has grown. Participants all have a knack for technology and plenty of unconventional ideas in their mind, and work in teams of three or four. With an open mind and enthusiasm for new things, they develop exciting concepts that no one has thought of before, making the teams grow closer together. „The best part of the Innovathon is that it harnesses the impressive knowledge and inventive spirit of SKIDATA team members to bring ideas to life and help shape the future of the company“, says Jeff, participant from the USA at this year´s SKIDATA Innovathon.

Research & development: inventiveness at SKIDATA

At SKIDATA, innovation is practically in our blood. Günther Walcher started the operative business in 1977 with the first printed ski ticket. What began as an idea 40 years ago has since developed into an internationally successful digital solution provider in access and visitor management. Still today, it is our employees´ pioneering spirit that drives the development of our IT business solutions forward. The result? SKIDATA has more than 100 patent families that have been developed and filed by the approximately 60 inventors in the SKIDATA team. Continuous research and development, a good work atmosphere that creates freedom for innovation and events such as the SKIDATA Innovathon make it possible. Our employees´ power of innovation is central to SKIDATA and new patent ideas are awarded once a year as part of a recognition event by the Executive Board.

Anyone with a keen eye for digital trends who is interested in working in SKIDATA´s creative and state-of-the-art environment can find job vacancies by visiting: https://www.skidata.com/en/corporate/jobs-careers/job-vacancies-at-skidata/

Note: The publication is accepted until 06.02.2018.

SKIDATA is a leading international company for access solutions and management. More than 10,000 SKIDATA installations in ski resorts, sports stadiums, major airports, shopping centers, cities, spas and wellness facilities, exhibition centers and amusement parks worldwide ensure safe and reliable access control for people and vehicles. SKIDATA places great value in offering solutions that are intuitive, easy to operate and secure. With their integrated concepts, SKIDATA helps clients optimize performance and maximize profits. The SKIDATA Group ( www.skidata.com) is a member of the publicly traded Swiss Kudelski Group ( www.nagra.com), a leading provider of digital security solutions.

Contact
SKIDATA AG
Mag. Belkis Etz
Untersbergstraße 40
5083 Grödig/Salzburg
Phone: +43 6246 888-0
E-Mail: jobs@skidata.com
Url: https://www.skidata.com/en/corporate/jobs-careers/